Plasmid Purification Market Size, Share & Trends Analysis growing at a CAGR of 12.09% from 2025 to 2033
The global plasmid purification market size was estimated at USD 1.91 billion in 2024 and is projected to reach USD 5.28 billion by 2033, growing at a CAGR of 12.09% from 2025 to 2033. The growing demand for recombinant DNA technology products and technological advancements in plasmid purification are some of the factors driving market growth.
Key Market Trends & Insights
- The North America plasmid purification market held the largest share of 40.69% of the global market in 2024.
- The plasmid purification industry in the U.S. is expected to grow significantly over the forecast period.
- By product & service, the products segment held the largest market share in 2024.
- Based on application, the cloning & protein expression segment held the largest market share of 48.90% in 2024.
- By end use, the academic & research institutes segment held the largest market share in 2024.
Market Size & Forecast
- 2024 Market Size: USD 1.91 Billion
- 2033 Projected Market Size: USD 5.28 Billion
- CAGR (2025-2033): 12.09%
- North America: Largest market in 2024
- Asia Pacific: Fastest growing market
Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/plasmid-purification-market-report/request/rs1
Moreover, the rising acceptance of cell and gene therapy to treat chronic diseases further propels market growth.
Growth of Gene Therapy and Cell Therapy
The rising prominence of gene and cell therapies is a major driver of growth in the plasmid purification industry. These advanced therapies rely heavily on high-purity plasmid DNA as a critical component for delivering genetic material into target cells. Plasmids serve as non-viral vectors in gene editing, gene replacement, and CAR-T cell therapies, making them essential for successfully developing and commercializing these treatments. With a rapidly expanding pipeline of gene therapy candidates, many of which are advancing through clinical trials, there is a growing demand for GMP-grade plasmid DNA that meets stringent regulatory and quality standards.
As gene therapies gain regulatory approval and expand into new therapeutic areas such as oncology, rare genetic disorders, and neurodegenerative diseases, the need for large-scale, scalable, and compliant plasmid purification technologies is intensifying. Biopharmaceutical companies, CDMOs, and research institutions invest in sophisticated purification platforms to meet this demand and support consistent production. This shift toward personalized and precision medicine is expanding the applications of plasmid DNA and reinforcing the plasmid purification industry as a foundational element of the broader gene therapy ecosystem.
